| # | Title | Journal | Year | Citations |
|---|
| 1 | Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial | Lancet Oncology, The | 2014 | 864 |
| 2 | Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial | Lancet, The | 2016 | 610 |
| 3 | Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations | Annals of Oncology | 2015 | 607 |
| 4 | Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial | Lancet Oncology, The | 2014 | 595 |
| 5 | Toward Minimal Residual Disease-Directed Therapy in Melanoma | Cell | 2018 | 514 |
| 6 | Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA) | Lancet Oncology, The | 2012 | 505 |
| 7 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer | Nature Genetics | 2013 | 493 |
| 8 | MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer | Clinical Cancer Research | 2017 | 492 |
| 9 | Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial | Lancet Oncology, The | 2018 | 491 |
| 10 | Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma | Journal of Clinical Oncology | 2022 | 446 |
| 11 | Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial | Lancet, The | 2017 | 444 |
| 12 | Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ | Annals of Oncology | 2021 | 381 |
| 13 | Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2018 | 380 |
| 14 | Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial | Lancet Oncology, The | 2018 | 333 |
| 15 | A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer | Nature Medicine | 2021 | 330 |
| 16 | Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial | Lancet Oncology, The | 2015 | 323 |
| 17 | EORTC elderly task force position paper: Approach to the older cancer patient | European Journal of Cancer | 2010 | 300 |
| 18 | Relevance of a systematic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric study | Annals of Oncology | 2013 | 285 |
| 19 | MYC High Level Gene Amplification Is a Distinctive Feature of Angiosarcomas after Irradiation or Chronic Lymphedema | American Journal of Pathology | 2010 | 276 |
| 20 | Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program | Annals of Oncology | 2018 | 246 |
| 21 | Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2022 | 213 |
| 22 | Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes | Lancet Oncology, The | 2011 | 212 |
| 23 | Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet Oncology, The | 2020 | 207 |
| 24 | Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study | Lancet Oncology, The | 2020 | 194 |
| 25 | Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas | JAMA - Journal of the American Medical Association | 2020 | 190 |
| 26 | Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy | Leukemia | 2015 | 171 |
| 27 | Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types | Cancer Discovery | 2016 | 157 |
| 28 | Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials) | Annals of Oncology | 2015 | 151 |
| 29 | Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial | Lancet Oncology, The | 2021 | 150 |
| 30 | Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up | Annals of Oncology | 2021 | 150 |
| 31 | Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study | Lancet Oncology, The | 2021 | 132 |
| 32 | Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170 | Nature Genetics | 2016 | 125 |
| 33 | Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG) | Lancet Oncology, The | 2021 | 121 |
| 34 | Identification of a novel, recurrent MBTD1‐CXorf67 fusion in low‐grade endometrial stromal sarcoma | International Journal of Cancer | 2014 | 117 |
| 35 | Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib | Annals of Oncology | 2011 | 116 |
| 36 | Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study | Lancet Haematology,the | 2015 | 115 |
| 37 | A phase I–II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors | Annals of Oncology | 2010 | 114 |
| 38 | Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial | European Journal of Cancer | 2017 | 108 |
| 39 | The effects of age on health-related quality of life in cancer populations: A pooled analysis of randomized controlled trials using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 involving 6024 cancer patients | European Journal of Cancer | 2015 | 105 |
| 40 | Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network | Annals of Oncology | 2020 | 103 |
| 41 | Functional decline in older patients with cancer receiving chemotherapy: A multicenter prospective study | Journal of Geriatric Oncology | 2017 | 99 |
| 42 | Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases | British Journal of Cancer | 2012 | 97 |
| 43 | Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI) | European Journal of Cancer | 2010 | 94 |
| 44 | Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group | Lancet Oncology, The | 2018 | 94 |
| 45 | Atropine, Hyoscine Butylbromide, or Scopolamine Are Equally Effective for the Treatment of Death Rattle in Terminal Care | Journal of Pain and Symptom Management | 2009 | 90 |
| 46 | Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study | European Journal of Cancer | 2011 | 88 |
| 47 | ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016 | ESMO Open | 2016 | 82 |
| 48 | Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial | Lancet Oncology, The | 2018 | 80 |
| 49 | Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies | Lancet Oncology, The | 2022 | 79 |
| 50 | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus | Nature Communications | 2016 | 78 |
